NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

The National Medical Products Administration (NMPA) has released the 110th batch of the Catalog of Reference Listed Drugs (RLD) for Chemical Generic Drugs, adding 28 new drug specifications and providing…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond
CompanyDrug

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis
CompanyDrug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer's Treatment Access
CompanyDrug

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC
CompanyDrug

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China’s First Senotherapeutics Biotech Backed by Top-Tier Investors

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China's First Senotherapeutics Biotech Backed by Top-Tier Investors

Reju Therapeutics, the first biotech company in China targeting aging biology, announced the completion of an oversubscribed Series A financing round of hundreds of millions of RMB. The round was jointly invested by Cathay Capital, Fosun Health Capital, Efund Capital,…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager
CompanyDeals

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry
Company

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry

Harbour BioMed's Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis
CompanyDrug

Harbour BioMed’s Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis

Merck's Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor
CompanyDrug

Merck’s Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

Novo Nordisk Secures NMPA Indication Update for Wegovy (semaglutide) in China – Expanded Label Now Covers Chinese BMI Criteria for Overweight and Obesity
CompanyDrug

Novo Nordisk Secures NMPA Indication Update for Wegovy (semaglutide) in China – Expanded Label Now Covers Chinese BMI Criteria for Overweight and Obesity

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
CompanyDeals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has entered into a definitive agreement with PepStar Therapeutics Limited to acquire its lead asset, HCXT‑2001, an investigational Phase I oral IL‑23…

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio
CompanyDeals

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline
CompanyDeals

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing
CompanyDeals

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio
CompanyDeals

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

More News

Sino Biopharm's CTTQ Wins China's First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch
Others

Sino Biopharm’s CTTQ Wins China’s First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch

Shandong Boan Doses First Subject in Phase I Trial of BA1203 – World's Only PD‑1/IL‑2 Antibody‑Cytokine Prodrug Advancing in Advanced Solid Tumors
CompanyDrug

Shandong Boan Doses First Subject in Phase I Trial of BA1203 – World’s Only PD‑1/IL‑2 Antibody‑Cytokine Prodrug Advancing in Advanced Solid Tumors

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise
Company

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise

Sichuan Biokin's Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid
CompanyDrug

Sichuan Biokin’s Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea
CompanyDrug

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo's ADC Wins Conditional Approval for HER2-Expressing Solid Tumors
CompanyDrug

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo’s ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed
Company

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

Show More